国际眼科纵览

• 综述 • 上一篇    下一篇

老视的药物治疗

吴庆晖1   钟华2   

  1. 1长沙爱尔眼科医院  410004;2昆明医科大学第一附属医院眼科  650032
  • 收稿日期:2019-11-26 出版日期:2020-06-22 发布日期:2020-06-22
  • 通讯作者: 钟华,Email: zhoculist@163.com

Pharmacological therapy of presbyopia

Wu Qinghui1, Zhong Hua2   

  1. 1Changsha Aier Eye Hospital, Changsha 410004, China; 2 Department of Ophthalmology, the First Affiliated Hospital of Kunming Medical University, Kunming 650032, China
  • Received:2019-11-26 Online:2020-06-22 Published:2020-06-22
  • Contact: Zhong Hua, Email: zhoculist@163.com

摘要: 目前老视的药物治疗主要包括增强调节能力的副交感神经激动剂如卡巴胆碱、匹罗卡品、PresbiDrops等,可刺激睫状肌收缩,增加睫状肌收缩力;其次是降低晶状体硬度、恢复晶状体弹性的硫辛酸类药物;以及利用光学原理增强患者视近调节能力的Liquid Vision等药物。但这些药物均存在局限性,如仅针对老视发生发展中的单个因素发挥作用,组合性药物机制不清,药物组合的最佳浓度、远期疗效、药物副作用及患者依从性等需进一步探究,且缺乏多中心研究及循证医学证据支撑。是否需根据患者调节力下降程度来调整用药浓度、频率及用药时间也需进一步验证。(国际眼科纵览, 2020, 44:182-186)

Abstract: The pharmacological therapy of presbyopia mainly includes parasympathetic agonists such as carbachol, pilocarpine, presbidrops, etc, which stimulate the contraction of ciliary muscle and enhance the accommodated ability of eye. Lipoic choline sulfate and Liquid Vision could be used to reduce the hardness of the lens, restore the elasticity of the lens and enhance the near vision ability. However, these drugs still have some limits, including working on single factor, unclear mechanism of combined drugs, lack of multi-center research support, and unclear the optimal concentration of the drug combination, long-term efficacy, drug side effects, patient compliance etc. Whether it is necessary to adjust the concentration, frequency and administration time according to the degree of accommodated ability decrease also needs further verification. (Int Rev Ophthalmol, 2020, 44:182-186)